March separate, strike together - Role of phosphorylated TAU in mitochondrial dysfunction in Alzheimer's disease

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1842, Issue 8, 2014, Pages 1258-1266

  Eckert, Anne ^a   Nisbet, Rebecca ^b   Grimm, Amandine ^a   Götz, Jürgen ^b  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Alzheimer's disease; Axonal transport; DRP1; Mitochondrion; Tauopathy

Indexed keywords

AMYLOID BETA PROTEIN; CYTOCHROME C OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); TAU PROTEIN;

ALZHEIMER DISEASE; BRAIN MITOCHONDRION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EXCITOTOXICITY; FUSION GENE; GENE MUTATION; HUMAN; MITOCHONDRIAL DYNAMICS; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEOMICS; REVIEW; SENESCENCE ACCELERATED MOUSE; TARGET CELL; TRANSGENIC MOUSE;

ALZHEIMER'S DISEASE; AXONAL TRANSPORT; DRP1; MITOCHONDRION; TAUOPATHY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; HUMANS; MITOCHONDRIA; PHOSPHORYLATION; PROTEIN TRANSPORT; TAU PROTEINS;

EID: 84903215603     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2013.08.013     Document Type: Review

References (137)

1. Dehmelt L., Halpain S. The MAP2/Tau family of microtubule-associated proteins. Genome Biol. 2005, 6:204.
2. Halpain S., Dehmelt L. The MAP1 family of microtubule-associated proteins. Genome Biol. 2006, 7:224.
3. Matus A. Microtubule-associated proteins and the determination of neuronal form. J Physiol. (Paris) 1990, 84:134-137.
4. McDermott J.B., Aamodt S., Aamodt E. PTL-1, a Caenorhabditis elegans gene whose products are homologous to the tau microtubule-associated proteins. Biochemistry 1996, 35:9415-9423.
5. Gordon P., Hingula L., Krasny M.L., Swienckowski J.L., Pokrywka N.J., Raley-Susman K.M. The invertebrate microtubule-associated protein PTL-1 functions in mechanosensation and development in Caenorhabditis elegans. Dev. Genes Evol. 2008, 218:541-551.
6. Chew Y.L., Fan X., Götz J., Nicholas H.R. Protein with tau-like repeats regulates neuronal integrity and lifespan in C. elegans. J. Cell Sci. 2013, 126:2079-2091.
7. Tashiro K., Hasegawa M., Ihara Y., Iwatsubo T. Somatodendritic localization of phosphorylated tau in neonatal and adult rat cerebral cortex. Neuroreport 1997, 8:2797-2801.
8. Weingarten M.D., Lockwood A.H., Hwo S.Y., Kirschner M.W. A protein factor essential for microtubule assembly. Proc. Natl. Acad. Sci. U. S. A. 1975, 72:1858-1862.
9. Grundke-Iqbal I., Iqbal K., Tung Y.C., Quinlan M., Wisniewski H.M., Binder L.I. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. U. S. A. 1986, 83:4913-4917.
10. Goedert M., Wischik C.M., Crowther R.A., Walker J.E., Klug A. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:4051-4055.
11. Chen F., David D., Ferrari A., Götz J. Posttranslational modifications of tau - role in human tauopathies and modeling in transgenic animals. Curr. Drug Targets 2004, 5:503-515.
12. Wang J.Z., Xia Y.Y., Grundke-Iqbal I., Iqbal K. Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration. J. Alzheimers Dis. 2013, 33(Suppl. 1):S123-S139.
13. Steinhilb M.L., Dias-Santagata D., Fulga T.A., Felch D.L., Feany M.B. Tau phosphorylation sites work in concert to promote neurotoxicity in vivo. Mol. Biol. Cell 2007, 18:5060-5068.
14. Akoury E., Pickhardt M., Gajda M., Biernat J., Mandelkow E., Zweckstetter M. Mechanistic basis of phenothiazine-driven inhibition of Tau aggregation. Angew. Chem. Int. Ed. Engl. 2013, 52:3511-3515.
15. Lee V.M., Balin B.J., Otvos L., Trojanowski J.Q. A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. Science 1991, 251:675-678.
16. Wischik C.M., Crowther R.A., Stewart M., Roth M. Subunit structure of paired helical filaments in Alzheimer's disease. J. Cell Biol. 1985, 100:1905-1912.
17. Wischik C.M., Edwards P.C., Lai R.Y., Gertz H.N., Xuereb J.H., Paykel E.S., Brayne C., Huppert F.A., Mukaetova-Ladinska E.B., Mena R., et al. Quantitative analysis of tau protein in paired helical filament preparations: implications for the role of tau protein phosphorylation in PHF assembly in Alzheimer's disease. Neurobiol. Aging 1995, 16:409-417. (discussion 418-431).
18. Clark L.N., Poorkaj P., Wszolek Z., Geschwind D.H., Nasreddine Z.S., Miller B., Li D., Payami H., Awert F., Markopoulou K., Andreadis A., D'Souza I., Lee V.M., Reed L., Trojanowski J.Q., Zhukareva V., Bird T., Schellenberg G., Wilhelmsen K.C. Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:13103-13107.
19. Hutton M., Lendon C.L., Rizzu P., Baker M., Froelich S., Houlden H., Pickering-Brown S., Chakraverty S., Isaacs A., Grover A., Hackett J., Adamson J., Lincoln S., Dickson D., Davies P., Petersen R.C., Stevens M., de Graaff E., Wauters E., van Baren J., Hillebrand M., Joosse M., Kwon J.M., Nowotny P., Heutink P., et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998, 393:702-705.
20. Poorkaj P., Bird T.D., Wijsman E., Nemens E., Garruto R.M., Anderson L., Andreadis A., Wiederholt W.C., Raskind M., Schellenberg G.D. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann. Neurol. 1998, 43:815-825.
21. Götz J., Ittner L.M. Animal models of Alzheimer's disease and frontotemporal dementia. Nat. Rev. Neurosci. 2008, 9:532-544.
22. Pennanen L., Welzl H., D'Adamo P., Nitsch R.M., Götz J. Accelerated extinction of conditioned taste aversion in P301L tau transgenic mice. Neurobiol. Dis. 2004, 15:500-509.
23. Pennanen L., Wolfer D.P., Nitsch R.M., Götz J. Impaired spatial reference memory and increased exploratory behavior in P301L tau transgenic mice. Genes Brain Behav. 2006, 5:369-379.
24. Le Corre S., Klafki H.W., Plesnila N., Hubinger G., Obermeier A., Sahagun H., Monse B., Seneci P., Lewis J., Eriksen J., Zehr C., Yue M., McGowan E., Dickson D.W., Hutton M., Roder H.M. An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:9673-9678.
25. van Eersel J., Ke Y.D., Liu X., Delerue F., Kril J.J., Götz J., Ittner L.M. Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:13888-13893.
26. Zhang X., Hermandez I., Rei D., Mair W., Laha J.K., Cornwell M.E., Cuny G.D., Tsai L.H., Steen J.A., Kosik K.S. Diaminothiazoles modify Tau phosphorylation and improve the tauopathy in mouse models. J. Biol. Chem. 2013, 288:22042-22056.
27. Deters N., Ittner L.M., Götz J. Substrate-specific reduction of PP2A activity exaggerates tau pathology. Biochem. Biophys. Res. Commun. 2009, 379:400-405.
28. Ittner L.M., Fath T., Ke Y.D., Bi M., van Eersel J., Li K.M., Gunning P., Götz J. Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:15997-16002.
29. Jacobson J., Duchen M.R. Interplay between mitochondria and cellular calcium signalling. Mol. Cell. Biochem. 2004, 256-257:209-218.
30. Schon E.A., Przedborski S. Mitochondria: the next (neurode)generation. Neuron 2011, 70:1033-1053.
31. Eckert A., Schmitt K., Götz J. Mitochondrial dysfunction - the beginning of the end in Alzheimer's disease? Separate and synergistic modes of tau and amyloid-beta toxicity. Alzheimers Res. Ther. 2011, 3:15.
32. Rugarli E.I., Langer T. Mitochondrial quality control: a matter of life and death for neurons. EMBO J. 2012, 31:1336-1349.
33. Chen H., Chan D.C. Mitochondrial dynamics - fusion, fission, movement, and mitophagy - in neurodegenerative diseases. Hum. Mol. Genet. 2009, 18:R169-R176.
34. Santos R.X., Correia S.C., Zhu X., Smith M.A., Moreira P.I., Castellani R.J., Nunomura A., Perry G. Mitochondrial DNA oxidative damage and repair in aging and Alzheimer's disease. Antioxid. Redox Signal. 2013, 18:2444-2457.
35. Moreira P.I., Santos M.S., Oliveira C.R. Alzheimer's disease: a lesson from mitochondrial dysfunction. Antioxid. Redox Signal. 2007, 9:1621-1630.
36. Chen H., Detmer S.A., Ewald A.J., Griffin E.E., Fraser S.E., Chan D.C. Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. J. Cell Biol. 2003, 160:189-200.
37. Alavi M.V., Bette S., Schimpf S., Schuettauf F., Schraermeyer U., Wehrl H.F., Ruttiger L., Beck S.C., Tonagel F., Pichler B.J., Knipper M., Peters T., Laufs J., Wissinger B. A splice site mutation in the murine Opa1 gene features pathology of autosomal dominant optic atrophy. Brain 2007, 130:1029-1042.
38. Davies V.J., Hollins A.J., Piechota M.J., Yip W., Davies J.R., White K.E., Nicols P.P., Boulton M.E., Votruba M. Opa1 deficiency in a mouse model of autosomal dominant optic atrophy impairs mitochondrial morphology, optic nerve structure and visual function. Hum. Mol. Genet. 2007, 16:1307-1318.
39. Wakabayashi J., Zhang Z., Wakabayashi N., Tamura Y., Fukaya M., Kensler T.W., Iijima M., Sesaki H. The dynamin-related GTPase Drp1 is required for embryonic and brain development in mice. J. Cell Biol. 2009, 186:805-816.
40. Ishihara N., Nomura M., Jofuku A., Kato H., Suzuki S.O., Masuda K., Otera H., Nakanishi Y., Nonaka I., Goto Y., Taguchi N., Morinaga H., Maeda M., Takayanagi R., Yokota S., Mihara K. Mitochondrial fission factor Drp1 is essential for embryonic development and synapse formation in mice. Nat. Cell Biol. 2009, 11:958-966.
41. Pham A.H., Meng S., Chu Q.N., Chan D.C. Loss of Mfn2 results in progressive, retrograde degeneration of dopaminergic neurons in the nigrostriatal circuit. Hum. Mol. Genet. 2012, 21:4817-4826.
42. Del Valle J., Bayod S., Camins A., Beas-Zarate C., Velazquez-Zamora D.A., Gonzalez-Burgos I., Pallas M. Dendritic spine abnormalities in hippocampal CA1 pyramidal neurons underlying memory deficits in the SAMP8 mouse model of Alzheimer's disease. J. Alzheimers Dis. 2012, 32:233-240.
43. Takeda T. Senescence-accelerated mouse (SAM): a biogerontological resource in aging research. Neurobiol. Aging 1999, 20:105-110.
44. Delerue F., Sjollema G., Whittle B., Kruger S., Andrews D., Gotz J. Single nucleotide variants (SNVs) define senescence-accelerated SAMP8 mice, a model of a geriatric condition. J. Alzheimers Dis. 2013, 36:349-363.
45. Tanisawa K., Mikami E., Fuku N., Honda Y., Honda S., Ohsawa I., Ito M., Endo S., Ihara K., Ohno K., Kishimoto Y., Ishigami A., Maruyama N., Sawabe M., Iseki H., Okazaki Y., Hasegawa-Ishii S., Takei S., Shimada A., Hosokawa M., Mori M., Higuchi K., Takeda T., Higuchi M., Tanaka M. Exome sequencing of senescence-accelerated mice (SAM) reveals deleterious mutations in degenerative disease-causing genes. BMC Genomics 2013, 14:248.
46. Pallas M., Camins A., Smith M.A., Perry G., Lee H.G., Casadesus G. From aging to Alzheimer's disease: unveiling "the switch" with the senescence-accelerated mouse model (SAMP8). J. Alzheimers Dis. 2008, 15:615-624.
47. Canudas A.M., Gutierrez-Cuesta J., Rodriguez M.I., Acuna-Castroviejo D., Sureda F.X., Camins A., Pallas M. Hyperphosphorylation of microtubule-associated protein tau in senescence-accelerated mouse (SAM). Mech. Ageing Dev. 2005, 126:1300-1304.
48. Takemura M., Nakamura S., Akiguchi I., Ueno M., Oka N., Ishikawa S., Shimada A., Kimura J., Takeda T. Beta/A4 protein-like immunoreactive granular structures in the brain of senescence-accelerated mouse. Am. J. Pathol. 1993, 142:1887-1897.
49. Fukunari A., Kato A., Sakai Y., Yoshimoto T., Ishiura S., Suzuki K., Nakajima T. Colocalization of prolyl endopeptidase and amyloid beta-peptide in brains of senescence-accelerated mouse. Neurosci. Lett. 1994, 176:201-204.
50. Kurokawa T., Sato E., Inoue A., Ishibashi S. Evidence that glucose metabolism is decreased in the cerebrum of aged female senescence-accelerated mouse; possible involvement of a low hexokinase activity. Neurosci. Lett. 1996, 214:45-48.
51. Omata N., Murata T., Fujibayashi Y., Waki A., Sadato N., Yoshimoto M., Wada Y., Yonekura Y. Age-related changes in energy production in fresh senescence-accelerated mouse brain slices as revealed by positron autoradiography. Dement. Geriatr. Cogn. Disord. 2001, 12:78-84.
52. Xu J., Shi C., Li Q., Wu J., Forster E.L., Yew D.T. Mitochondrial dysfunction in platelets and hippocampi of senescence-accelerated mice. J. Bioenerg. Biomembr. 2007, 39:195-202.
53. Shi C., Xiao S., Liu J., Guo K., Wu F., Yew D.T., Xu J. Ginkgo biloba extract EGb761 protects against aging-associated mitochondrial dysfunction in platelets and hippocampi of SAMP8 mice. Platelets 2010, 21:373-379.
54. Kurokawa T., Asada S., Nishitani S., Hazeki O. Age-related changes in manganese superoxide dismutase activity in the cerebral cortex of senescence-accelerated prone and resistant mouse. Neurosci. Lett. 2001, 298:135-138.
55. Sato E., Oda N., Ozaki N., Hashimoto S., Kurokawa T., Ishibashi S. Early and transient increase in oxidative stress in the cerebral cortex of senescence-accelerated mouse. Mech. Ageing Dev. 1996, 86:105-114.
56. Okatani Y., Wakatsuki A., Reiter R.J., Miyahara Y. Melatonin reduces oxidative damage of neural lipids and proteins in senescence-accelerated mouse. Neurobiol. Aging 2002, 23:639-644.
57. Yasui F., Ishibashi M., Matsugo S., Kojo S., Oomura Y., Sasaki K. Brain lipid hydroperoxide level increases in senescence-accelerated mice at an early age. Neurosci. Lett. 2003, 350:66-68.
58. Kitamura Y., Zhao X.H., Ohnuki T., Nomura Y. Ligand-binding characteristics of [3H]QNB, [3H]prazosin, [3H]rauwolscine, [3H]TCP and [3H]nitrendipine to cerebral cortical and hippocampal membranes of senescence accelerated mouse. Neurosci. Lett. 1989, 106:334-338.
59. Klein J.A., Longo-Guess C.M., Rossmann M.P., Seburn K.L., Hurd R.E., Frankel W.N., Bronson R.T., Ackerman S.L. The Harlequin mouse mutation downregulates apoptosis-inducing factor. Nature 2002, 419:367-374.
60. Kulic L., Wollmer M.A., Rhein V., Pagani L., Kuehnle K., Cattepoel S., Tracy J., Eckert A., Nitsch R.M. Combined expression of tau and the Harlequin mouse mutation leads to increased mitochondrial dysfunction, tau pathology and neurodegeneration. Neurobiol. Aging 2011, 32:1827-1838.
61. Hoerndli F., David D., Götz J. Functional genomics meets neurodegenerative disorders, part II: application and data integration. Prog. Neurobiol. 2005, 76:169-188.
62. Götz J., Chen F., Barmettler R., Nitsch R.M. Tau filament formation in transgenic mice expressing P301L Tau. J. Biol. Chem. 2001, 276:529-534.
63. Deters N., Ittner L.M., Götz J. Divergent phosphorylation pattern of tau in P301L tau transgenic mice. Eur. J. Neurosci. 2008, 28:137-147.
64. David D.C., Hauptmann S., Scherping I., Schuessel K., Keil U., Rizzu P., Ravid R., Dröse S., Brandt U., Müller W.E., Eckert E., Götz J. Proteomic and functional analysis reveal a mitochondrial dysfunction in P301L tau transgenic mice. J. Biol. Chem. 2005, 280:23802-23814.
65. Keil U., Bonert A., Marques C.A., Scherping I., Weyermann J., Strosznajder J.B., Muller-Spahn F., Haass C., Czech C., Pradier L., Muller W.E., Eckert A. Amyloid beta-induced changes in nitric oxide production and mitochondrial activity lead to apoptosis. J. Biol. Chem. 2004, 279:50310-50320.
66. Lim Y.-A., Rhein V., Baysang G., Meier F., Poljak A., Raftery M., Ittner L.M., Guilhaus M., Eckert A., Götz J. Abeta and human amylin share a common toxicity pathway via mitochondrial dysfunction. Proteomics 2010, 10:1621-1633.
67. Lustbader J.W., Cirilli M., Lin C., Xu H.W., Takuma K., Wang N., Caspersen C., Chen X., Pollak S., Chaney M., Trinchese F., Liu S., Gunn-Moore F., Lue L.F., Walker D.G., Kuppusamy P., Zewier Z.L., Arancio O., Stern D., Yan S.S., Wu H. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science 2004, 304:448-452.
68. Manczak M., Reddy P.H. Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer's disease. Hum. Mol. Genet. 2012, 21:5131-5146.
69. Winton M.J., Lee E.B., Sun E., Wong M.M., Leight S., Zhang B., Trojanowski J.Q., Lee V.M. Intraneuronal APP, not free A{beta} peptides in 3xTg-AD mice: implications for Tau versus A{beta}-mediated Alzheimer neurodegeneration. J. Neurosci. 2011, 31:7691-7699.
70. Rhein V., Baysang G., Rao S., Meier F., Bonert A., Muller-Spahn F., Eckert A. Amyloid-beta leads to impaired cellular respiration, energy production and mitochondrial electron chain complex activities in human neuroblastoma cells. Cell. Mol. Neurobiol. 2009, 29:1063-1071.
71. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles, intracellular abeta and synaptic dysfunction. Neuron 2003, 39:409-421.
72. Yao J., Irwin R.W., Zhao L., Nilsen J., Hamilton R.T., Brinton R.D. Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:14670-14675.
73. Chou J.L., Shenoy D.V., Thomas N., Choudhary P.K., Laferla F.M., Goodman S.R., Breen G.A. Early dysregulation of the mitochondrial proteome in a mouse model of Alzheimer's disease. J. Proteome 2011, 74:466-479.
74. Hollenbeck P.J. The pattern and mechanism of mitochondrial transport in axons. Front. Biosci. 1996, 1:d91-d102.
75. Ishihara T., Hong M., Zhang B., Nakagawa Y., Lee M.K., Trojanowski J.Q., Lee V.M. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron 1999, 24:751-762.
76. Ittner L.M., Ke Y.D., Götz J. Phosphorylated Tau interacts with c-Jun N-terminal kinase-interacting protein 1 (JIP1) in Alzheimer disease. J. Biol. Chem. 2009, 284:20909-20916.
77. Kanaan N.M., Morfini G.A., LaPointe N.E., Pigino G.F., Patterson K.R., Song Y., Andreadis A., Fu Y., Brady S.T., Binder L.I. Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases. J. Neurosci. 2011, 31:9858-9868.
78. Morel M., Authelet M., Dedecker R., Brion J.P. Glycogen synthase kinase-3beta and the p25 activator of cyclin dependent kinase 5 increase pausing of mitochondria in neurons. Neuroscience 2010, 167:1044-1056.
79. Dubey M., Chaudhury P., Kabiru H., Shea T.B. Tau inhibits anterograde axonal transport and perturbs stability in growing axonal neurites in part by displacing kinesin cargo: neurofilaments attenuate tau-mediated neurite instability. Cell Motil. Cytoskeleton 2008, 65:89-99.
80. Fatouros C., Pir G.J., Biernat J., Koushika S.P., Mandelkow E., Mandelkow E.M., Schmidt E., Baumeister R. Inhibition of tau aggregation in a novel Caenorhabditis elegans model of tauopathy mitigates proteotoxicity. Hum. Mol. Genet. 2012, 21:3587-3603.
81. Stoothoff W., Jones P.B., Spires-Jones T.L., Joyner D., Chhabra E., Bercury K., Fan Z., Xie H., Bacskai B., Edd J., Irimia D., Hyman B.T. Differential effect of three-repeat and four-repeat tau on mitochondrial axonal transport. J. Neurochem. 2009, 111:417-427.
82. Hasegawa M. Biochemistry and molecular biology of tauopathies. Neuropathol. 2006, 26:484-490.
83. Tsuboi Y. Neuropathology of familial tauopathy. Neuropathol. 2006, 26:471-474.
84. Calkins M.J., Manczak M., Mao P., Shirendeb U., Reddy P.H. Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer's disease. Hum. Mol. Genet. 2011, 20:4515-4529.
85. Tang Y., Scott D.A., Das U., Edland S.D., Radomski K., Koo E.H., Roy S. Early and selective impairments in axonal transport kinetics of synaptic cargoes induced by soluble amyloid beta-protein oligomers. Traffic 2012, 13:681-693.
86. Vossel K.A., Zhang K., Brodbeck J., Daub A.C., Sharma P., Finkbeiner S., Cui B., Mucke L. Tau reduction prevents Abeta-induced defects in axonal transport. Science 2010, 330:198.
87. Iijima-Ando K., Sekiya M., Maruko-Otake A., Ohtake Y., Suzuki E., Lu B., Iijima K.M. Loss of axonal mitochondria promotes tau-mediated neurodegeneration and Alzheimer's disease-related tau phosphorylation via PAR-1. PLoS Genet. 2012, 8:e1002918.
88. Shahpasand K., Uemura I., Saito T., Asano T., Hata K., Shibata K., Toyoshima Y., Hasegawa M., Hisanaga S. Regulation of mitochondrial transport and inter-microtubule spacing by tau phosphorylation at the sites hyperphosphorylated in Alzheimer's disease. J. Neurosci. 2012, 32:2430-2441.
89. Mertens J., Stuber K., Poppe D., Doerr J., Ladewig J., Brustle O., Koch P. Embryonic stem cell-based modeling of tau pathology in human neurons. Am. J. Pathol. 2013, 182:1769-1779.
90. Gilley J., Seereeram A., Ando K., Mosely S., Andrews S., Kerschensteiner M., Misgeld T., Brion J.P., Anderton B., Hanger D.P., Coleman M.P. Age-dependent axonal transport and locomotor changes and tau hypophosphorylation in a "P301L" tau knockin mouse. Neurobiol. Aging 2012, 33:621.e1-621.e15.
91. Falzone T.L., Stokin G.B., Lillo C., Rodrigues E.M., Westerman E.L., Williams D.S., Goldstein L.S. Axonal stress kinase activation and tau misbehavior induced by kinesin-1 transport defects. J. Neurosci. 2009, 29:5758-5767.
92. Kuznetsov A.V., Margreiter R. Heterogeneity of mitochondria and mitochondrial function within cells as another level of mitochondrial complexity. Int. J. Mol. Sci. 2009, 10:1911-1929.
93. Waagepetersen H.S., Hansen G.H., Fenger K., Lindsay J.G., Gibson G., Schousboe A. Cellular mitochondrial heterogeneity in cultured astrocytes as demonstrated by immunogold labeling of alpha-ketoglutarate dehydrogenase. Glia 2006, 53:225-231.
94. Overly C.C., Rieff H.I., Hollenbeck P.J. Organelle motility and metabolism in axons vs dendrites of cultured hippocampal neurons. J. Cell Sci. 1996, 109(Pt 5):971-980.
95. Popov V., Medvedev N.I., Davies H.A., Stewart M.G. Mitochondria form a filamentous reticular network in hippocampal dendrites but are present as discrete bodies in axons: a three-dimensional ultrastructural study. J. Comp. Neurol. 2005, 492:50-65.
96. Vos M., Lauwers E., Verstreken P. Synaptic mitochondria in synaptic transmission and organization of vesicle pools in health and disease. Frontiers synaptic neurosci. 2010, 2:139.
97. 2+ overload than nonsynaptic mitochondria. J. Biol. Chem. 2006, 281:11658-11668.
98. Chang D.T., Honick A.S., Reynolds I.J. Mitochondrial trafficking to synapses in cultured primary cortical neurons. J. Neurosci. 2006, 26:7035-7045.
99. Duboff B., Feany M., Götz J. Why size matters - balancing mitochondrial dynamics in Alzheimer's disease. Trends Neurosci. 2013, 36:325-335.
100. Meeusen S., DeVay R., Block J., Cassidy-Stone A., Wayson S., McCaffery J.M., Nunnari J. Mitochondrial inner-membrane fusion and crista maintenance requires the dynamin-related GTPase Mgm1. Cell 2006, 127:383-395.
101. Song Z., Ghochani M., McCaffery J.M., Frey T.G., Chan D.C. Mitofusins and OPA1 mediate sequential steps in mitochondrial membrane fusion. Mol. Biol. Cell 2009, 20:3525-3532.
102. Palmer C.S., Osellame L.D., Stojanovski D., Ryan M.T. The regulation of mitochondrial morphology: intricate mechanisms and dynamic machinery. Cell. Signal. 2011, 23:1534-1545.
103. Palmer C.S., Osellame L.D., Laine D., Koutsopoulos O.S., Frazier A.E., Ryan M.T. MiD49 and MiD51, new components of the mitochondrial fission machinery. EMBO Rep. 2011, 12:565-573.
104. Kageyama Y., Zhang Z., Roda R., Fukaya M., Wakabayashi J., Wakabayashi N., Kensler T.W., Reddy P.H., Iijima M., Sesaki H. Mitochondrial division ensures the survival of postmitotic neurons by suppressing oxidative damage. J. Cell Biol. 2012, 197:535-551.
105. Tondera D., Grandemange S., Jourdain A., Karbowski M., Mattenberger Y., Herzig S., Da Cruz S., Clerc P., Raschke I., Merkwirth C., Ehses S., Krause F., Chan D.C., Alexander C., Bauer C., Youle R., Langer T., Martinou J.C. SLP-2 is required for stress-induced mitochondrial hyperfusion. EMBO J. 2009, 28:1589-1600.
106. Wang X., Su B., Lee H.G., Li X., Perry G., Smith M.A., Zhu X. Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. J. Neurosci. 2009, 29:9090-9103.
107. Manczak M., Calkins M.J., Reddy P.H. Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: implications for neuronal damage. Hum. Mol. Genet. 2011, 20:2495-2509.
108. Wang X., Su B., Fujioka H., Zhu X. Dynamin-like protein 1 reduction underlies mitochondrial morphology and distribution abnormalities in fibroblasts from sporadic Alzheimer's disease patients. Am. J. Pathol. 2008, 173:470-482.
109. Cho D.H., Nakamura T., Fang J., Cieplak P., Godzik A., Gu Z., Lipton S.A. S-nitrosylation of Drp1 mediates beta-amyloid-related mitochondrial fission and neuronal injury. Science 2009, 324:102-105.
110. Wang X., Su B., Siedlak S.L., Moreira P.I., Fujioka H., Wang Y., Casadesus G., Zhu X. Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:19318-19323.
111. Calkins M.J., Reddy P.H. Assessment of newly synthesized mitochondrial DNA using BrdU labeling in primary neurons from Alzheimer's disease mice: implications for impaired mitochondrial biogenesis and synaptic damage. Biochim. Biophys. Acta 2011, 1812:1182-1189.
112. Khurana V., Elson-Schwab I., Fulga T.A., Sharp K.A., Loewen C.A., Mulkearns E., Tyynela J., Scherzer C.R., Feany M.B. Lysosomal dysfunction promotes cleavage and neurotoxicity of tau in vivo. PLoS gen. 2010, 6:e1001026.
113. Quintanilla R.A., Dolan P.J., Jin Y.N., Johnson G.V. Truncated tau and Abeta cooperatively impair mitochondria in primary neurons. Neurobiol. Aging 2012, 33:619.e625-619.e635.
114. Quintanilla R.A., Matthews-Roberson T.A., Dolan P.J., Johnson G.V. Caspase-cleaved tau expression induces mitochondrial dysfunction in immortalized cortical neurons: implications for the pathogenesis of Alzheimer disease. J. Biol. Chem. 2009, 284:18754-18766.
115. Schulz K.L., Eckert A., Rhein V., Mai S., Haase W., Reichert A.S., Jendrach M., Muller W.E., Leuner K. A new link to mitochondrial impairment in tauopathies. Mol. Neurobiol. 2012, 46:205-216.
116. Kopeikina K.J., Carlson G.A., Pitstick R., Ludvigson A.E., Peters A., Luebke J.I., Koffie R.M., Frosch M.P., Hyman B.T., Spires-Jones T.L. Tau accumulation causes mitochondrial distribution deficits in neurons in a mouse model of tauopathy and in human Alzheimer's disease brain. Am. J. Pathol. 2011, 179:2071-2082.
117. Fulga T.A., Elson-Schwab I., Khurana V., Steinhilb M.L., Spires T.L., Hyman B.T., Feany M.B. Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo. Nat. Cell Biol. 2007, 9:139-148.
118. Duboff B., Götz J., Feany M.B. Tau promotes neurodegeneration via DRP1 mislocalization in vivo. Neuron 2012, 75:618-632.
119. Korobova F., Ramabhadran V., Higgs H.N. An actin-dependent step in mitochondrial fission mediated by the ER-associated formin INF2. Science 2013, 339:464-467.
120. Twig G., Hyde B., Shirihai O.S. Mitochondrial fusion, fission and autophagy as a quality control axis: the bioenergetic view. Biochim. Biophys. Acta 2008, 1777:1092-1097.
121. Palop J.J., Chin J., Roberson E.D., Wang J., Thwin M.T., Bien-Ly N., Yoo J., Ho K.O., Yu G.Q., Kreitzer A., Finkbeiner S., Noebels J.L., Mucke L. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 2007, 55:697-711.
122. Palop J.J., Mucke L. Epilepsy and cognitive impairments in Alzheimer disease. Arch. Neurol. 2009, 66:435-440.
123. Nakamura T., Lipton S.A. Redox modulation by S-nitrosylation contributes to protein misfolding, mitochondrial dynamics, and neuronal synaptic damage in neurodegenerative diseases. Cell Death Differ. 2011, 18:1478-1486.
124. Brennan-Minnella A.M., Shen Y., Swanson R.A. Phosphoinositide 3-kinase couples NMDA receptors to superoxide release in excitotoxic neuronal death. Cell death dis. 2013, 4:e580.
125. Sakono M., Zako T. Amyloid oligomers: formation and toxicity of Abeta oligomers. FEBS J. 2010, 277:1348-1358.
126. Doulias P.T., Tenopoulou M., Greene J.L., Raju K., Ischiropoulos H. Nitric oxide regulates mitochondrial fatty acid metabolism through reversible protein S-nitrosylation. Sci. Signal. 2013, 6:rs1.
127. Grohm J., Kim S.W., Mamrak U., Tobaben S., Cassidy-Stone A., Nunnari J., Plesnila N., Culmsee C. Inhibition of Drp1 provides neuroprotection in vitro and in vivo. Cell Death Differ. 2012, 19:1446-1458.
128. Hardy J. Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal. J. Alzheimers Dis. 2006, 9:151-153.
129. Lewis J., Dickson D.W., Lin W.-L., Chisholm L., Corral A., Jones G., Yen S.-H., Sahara N., Skipper L., Yager D., Eckman C., Hardy J., Hutton M., McGowan E. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant Tau and APP. Science 2001, 293:1487-1491.
130. Götz J., Chen F., van Dorpe J., Nitsch R.M. Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Abeta 42 fibrils. Science 2001, 293:1491-1495.
131. Rapoport M., Dawson H.N., Binder L.I., Vitek M.P., Ferreira A. Tau is essential to beta-amyloid-induced neurotoxicity. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:6364-6369.
132. Roberson E.D., Scearce-Levie K., Palop J.J., Yan F., Cheng I.H., Wu T., Gerstein H., Yu G.Q., Mucke L. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 2007, 316:750-754.
133. Ittner L.M., Ke Y.D., Delerue F., Bi M., Gladbach A., van Eersel J., Wolfing H., Chieng B.C., Christie M.J., Napier I.A., Eckert A., Staufenbiel M., Hardeman E., Götz J. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 2010, 142:387-397.
134. Ittner L.M., Götz J. Amyloid-beta and tau - a toxic pas de deux in Alzheimer's disease. Nat. Rev. Neurosci. 2011, 12:65-72.
135. Haass C., Mandelkow E. Fyn-tau-amyloid: a toxic triad. Cell 2010, 142:356-358.
136. Roberson E.D., Halabisky B., Yoo J.W., Yao J., Chin J., Yan F., Wu T., Hamto P., Devidze N., Yu G.Q., Palop J.J., Noebels J.L., Mucke L. Amyloid-beta/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J. Neurosci. 2011, 31:700-711.
137. Tackenberg C., Grinschgl S., Trutzel A., Santuccione A.C., Frey M.C., Konietzko U., Grimm J., Brandt R., Nitsch R.M. NMDA receptor subunit composition determines beta-amyloid-induced neurodegeneration and synaptic loss. Cell death dis. 2013, 4:e608.